Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report
BackgroundCancer-related inflammation contributes to the progression of malignancies and considerably affects therapeutic outcomes. IL-6 acts as a main mediator of both local and systemic inflammatory responses. Although IL-6 therapies have been successful in the treatment of inflammatory conditions...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1530387/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850272162020065280 |
|---|---|
| author | Yushi Cai Xuan Jin Yun Dai |
| author_facet | Yushi Cai Xuan Jin Yun Dai |
| author_sort | Yushi Cai |
| collection | DOAJ |
| description | BackgroundCancer-related inflammation contributes to the progression of malignancies and considerably affects therapeutic outcomes. IL-6 acts as a main mediator of both local and systemic inflammatory responses. Although IL-6 therapies have been successful in the treatment of inflammatory conditions, there has been little experience in patients with cancer.Case presentationA 66-year-old man was diagnosed with gastroesophageal junction squamous cell carcinoma (stage IV) with liver metastasis. The patient presented with notable cancer-associated systemic inflammatory symptoms, and experienced disease progression after initial two cycles of anti-PD-1 combined with chemotherapy. After tocilizumab treatment, the symptoms improved rapidly. The patient showed favorable response to subsequent anti-PD-1 plus second-line chemotherapy, and survived without disease progression.ConclusionTargeting IL-6 holds promise for the management of cancer-associated inflammation and improvement of therapeutic outcomes. |
| format | Article |
| id | doaj-art-cb53115ebf4345ac8dcbbb29c5d33d47 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-cb53115ebf4345ac8dcbbb29c5d33d472025-08-20T01:51:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-04-011510.3389/fonc.2025.15303871530387Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case reportYushi Cai0Xuan Jin1Yun Dai2Department of Gastroenterology, Peking University First Hospital, Beijing, ChinaDepartment of Oncology, Peking University First Hospital, Beijing, ChinaDepartment of Gastroenterology, Peking University First Hospital, Beijing, ChinaBackgroundCancer-related inflammation contributes to the progression of malignancies and considerably affects therapeutic outcomes. IL-6 acts as a main mediator of both local and systemic inflammatory responses. Although IL-6 therapies have been successful in the treatment of inflammatory conditions, there has been little experience in patients with cancer.Case presentationA 66-year-old man was diagnosed with gastroesophageal junction squamous cell carcinoma (stage IV) with liver metastasis. The patient presented with notable cancer-associated systemic inflammatory symptoms, and experienced disease progression after initial two cycles of anti-PD-1 combined with chemotherapy. After tocilizumab treatment, the symptoms improved rapidly. The patient showed favorable response to subsequent anti-PD-1 plus second-line chemotherapy, and survived without disease progression.ConclusionTargeting IL-6 holds promise for the management of cancer-associated inflammation and improvement of therapeutic outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2025.1530387/fullcancer-associated inflammationimmune checkpoint inhibitorIL-6tocilizumabchemotherapy |
| spellingShingle | Yushi Cai Xuan Jin Yun Dai Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report Frontiers in Oncology cancer-associated inflammation immune checkpoint inhibitor IL-6 tocilizumab chemotherapy |
| title | Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report |
| title_full | Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report |
| title_fullStr | Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report |
| title_full_unstemmed | Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report |
| title_short | Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report |
| title_sort | tocilizumab improves the efficacy of anti pd 1 in a patient with advanced gastroesophageal junction cancer a case report |
| topic | cancer-associated inflammation immune checkpoint inhibitor IL-6 tocilizumab chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1530387/full |
| work_keys_str_mv | AT yushicai tocilizumabimprovestheefficacyofantipd1inapatientwithadvancedgastroesophagealjunctioncanceracasereport AT xuanjin tocilizumabimprovestheefficacyofantipd1inapatientwithadvancedgastroesophagealjunctioncanceracasereport AT yundai tocilizumabimprovestheefficacyofantipd1inapatientwithadvancedgastroesophagealjunctioncanceracasereport |